Web mishap linked with Amarin rally

Amarin's ($AMRN) stock price jumped 9% Thursday after the Ireland-based drugmaker put an outdated website online that stated its experimental omega-3 drug had been approved. As Reuters reports, the FDA isn't expect to decide whether to green-light the drug for patients with high triglycerides in their blood until July 26, but investors are obviously watching the status of the drug closely. Amarin explained how the erroneous information surfaced online in a regulatory filing. Article

 

 

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.